KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash from Operations (2020 - 2025)

Historic Cash from Operations for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to -$52.6 million.

  • AbCellera Biologics' Cash from Operations fell 8209.96% to -$52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$104.6 million, marking a year-over-year increase of 1299.44%. This contributed to the annual value of -$108.6 million for FY2024, which is 14740.98% down from last year.
  • AbCellera Biologics' Cash from Operations amounted to -$52.6 million in Q3 2025, which was down 8209.96% from -$32.4 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Cash from Operations registered a high of $273.0 million during Q2 2022, and its lowest value of -$126.8 million during Q3 2022.
  • Over the past 5 years, AbCellera Biologics' median Cash from Operations value was -$11.6 million (recorded in 2025), while the average stood at $14.4 million.
  • Per our database at Business Quant, AbCellera Biologics' Cash from Operations soared by 1443835.08% in 2021 and then tumbled by 2714716.98% in 2024.
  • Quarter analysis of 5 years shows AbCellera Biologics' Cash from Operations stood at -$16.7 million in 2021, then skyrocketed by 284.97% to $30.9 million in 2022, then tumbled by 163.44% to -$19.6 million in 2023, then surged by 59.21% to -$8.0 million in 2024, then tumbled by 557.43% to -$52.6 million in 2025.
  • Its last three reported values are -$52.6 million in Q3 2025, -$32.4 million for Q2 2025, and -$11.6 million during Q1 2025.